Clinical Trial: Lemborexant in Delayed Sleep Phase Syndrome

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874855) titled 'Lemborexant in Delayed Sleep Phase Syndrome' on March 07.

Brief Summary: The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy.

In this 2-year study, we will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.

Study Start Date: March 13, 2023

Study Type: INTERVENTIONAL

Condition: ...